{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:46:39Z","timestamp":1794015999182,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017636","name":"Pfizer's Centers for Therapeutic Innovation","doi-asserted-by":"publisher","award":["53233907"],"award-info":[{"award-number":["53233907"]}],"id":[{"id":"10.13039\/100017636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02313-9","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:03:52Z","timestamp":1780052632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world data for a CDK4\/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+\/HER2\u2212 metastatic breast cancer: a multicenter prospective cohort study"],"prefix":"10.1186","volume":"28","author":[{"given":"Takashi","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Takao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takabatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimitsu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uhi","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Narui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2313_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25\u201335.","journal-title":"Lancet Oncol"},{"key":"2313_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"2313_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro JIS, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339.","journal-title":"Lancet Oncol"},{"key":"2313_CR4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024;42:994\u20131000.","journal-title":"J Clin Oncol"},{"key":"2313_CR5","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926\u201336.","journal-title":"N Engl J Med"},{"key":"2313_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s10147-018-1353-9","volume":"24","author":"H Mukai","year":"2018","unstructured":"Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, et al. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Int J Clin Oncol. 2018;24:274\u201387.","journal-title":"Int J Clin Oncol"},{"key":"2313_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10147-018-1359-3","volume":"24","author":"N Masuda","year":"2019","unstructured":"Masuda N, Inoue K, Nakamura R, Rai Y, Mukai H, Ohno S, et al. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. Int J Clin Oncol. 2019;24:262\u201373.","journal-title":"Int J Clin Oncol"},{"key":"2313_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","volume":"636","author":"GS Sonke","year":"2024","unstructured":"Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, et al. Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer. Nature. 2024;636:474\u201380.","journal-title":"Nature"},{"key":"2313_CR9","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1186\/s12885-018-4978-1","volume":"18","author":"A van Ommen-Nijhof","year":"2018","unstructured":"van Ommen-Nijhof A, Konings IR, van Zeijl CJJ, Uyl-de Groot CA, van der Noort V, Jager A, et al. Selecting the optimal position of CDK4\/6 inhibitors in hormone receptor-positive advanced breast cancer\u2014the SONIA study: study protocol for a randomized controlled trial. BMC Cancer. 2018;18:1146.","journal-title":"BMC Cancer"},{"issue":"1","key":"2313_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13058-018-0958-2","volume":"20","author":"JK Kish","year":"2018","unstructured":"Kish JK, Ward MA, Garofalo D, Ahmed HV, McRoy L, Laney J, et al. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced\/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res. 2018;20:37.","journal-title":"Breast Cancer Res"},{"key":"2313_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-019-05176-1","volume":"176","author":"L Varella","year":"2019","unstructured":"Varella L, Eziokwu AS, Jia X, Kruse M, Moore HCF, Budd GT, et al. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res Treat. 2019;176:429\u201334.","journal-title":"Breast Cancer Res Treat"},{"key":"2313_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","volume":"23","author":"A DeMichele","year":"2021","unstructured":"DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, et al. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021;23:37.","journal-title":"Breast Cancer Res"},{"key":"2313_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12282-024-01575-5","volume":"31","author":"T Yoshinami","year":"2024","unstructured":"Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, et al. Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast Cancer. 2024;31:621\u201332.","journal-title":"Breast Cancer"},{"key":"2313_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s12282-025-01689-4","volume":"32","author":"SE Nagai","year":"2025","unstructured":"Nagai SE, Hattori M, Yoshinami T, Masuda H, Okamura T, Watanabe K, et al. Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+\/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study). Breast Cancer. 2025;32:705\u201315.","journal-title":"Breast Cancer"},{"key":"2313_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10549-024-07287-w","volume":"206","author":"N Mart\u00ednez-Ja\u00f1ez","year":"2024","unstructured":"Mart\u00ednez-Ja\u00f1ez N, Ezquerra MB, Manso Sanchez LM, Carrasco FH, Torres AA, Morales S, et al. First-line therapy with palbociclib in patients with advanced HR+\/HER2- breast cancer: the real-life study PALBOSPAIN. Breast Cancer Res Treat. 2024;206:317\u201328.","journal-title":"Breast Cancer Res Treat"},{"key":"2313_CR16","doi-asserted-by":"publisher","first-page":"S1290","DOI":"10.1016\/j.annonc.2021.08.2090","volume":"32","author":"GN Hortobagyi","year":"2021","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L. Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive\/human epidermal growth factor receptor 2 negative (HR+\/HER2\u2212) advanced breast cancer (ABC) treated with endocrine therapy (ET) \u00b1 ribociclib (RIB). Ann Oncol. 2021;32:S1290-1.","journal-title":"Ann Oncol"},{"issue":"17","key":"2313_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003","volume":"40","author":"RS Finn","year":"2022","unstructured":"Finn RS, Rugo HS, Dieras VC, Harbeck N, Im SA, Gelmon KA, et al. Overall survival (OS) with first-line Palbociclib plus Letrozole (PAL\u2009+\u2009LET) versus placebo plus Letrozole (PBO\u2009+\u2009LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer (ER+\/HER2\u2212\u2009ABC): analyses from PALOMA-2. J Clin Oncol. 2022;40(17):LBA1003.","journal-title":"J Clin Oncol"},{"key":"2313_CR18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, Toi M, Huober J, Sohn J, Tr\u00e9dan O, Park IH, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\u2009\u2212\u2009advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35:718\u201327.","journal-title":"Ann Oncol"},{"key":"2313_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/jamaoncol.2023.2000","volume":"9","author":"CC O'Sullivan","year":"2023","unstructured":"O\u2019Sullivan CC, Clarke R, Goetz MP, Robertson J. Cyclin-dependent kinase 4\/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: a review. JAMA Oncol. 2023;9:1273\u201382.","journal-title":"JAMA Oncol"},{"key":"2313_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.14740\/wjon1507","volume":"13","author":"K Narui","year":"2022","unstructured":"Narui K, Ishikawa T, Taira N, Uemura Y, Mukai H. Prospective cohort study of Palbociclib treatment in postmenopausal patients with unresectable and metastatic hormone receptor-positive breast cancer: study protocol for a CSPOR-BC Palbociclib cohort trial. World J Oncol. 2022;13:190\u20134.","journal-title":"World J Oncol"},{"issue":"25","key":"2313_CR21","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Toi MM, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in combination with Fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2313_CR22","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465\u201372.","journal-title":"J Clin Oncol"},{"key":"2313_CR23","volume":"19","author":"N Wortelboer","year":"2026","unstructured":"Wortelboer N, van Ommen-Nijhof A, Konings IR, van der Noort V, van den Pol E, Guerrero P\u00e1ez C, et al. Overall survival with first-line vs second-line CDK4\/6 inhibitor use in advanced breast cancer: a randomized clinical trial. JAMA Oncol. 2026;19: e256585.","journal-title":"JAMA Oncol."},{"issue":"7","key":"2313_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105309","volume":"10","author":"A Llombart-Cussac","year":"2025","unstructured":"Llombart-Cussac A, P\u00e9rez-Garc\u00eda JM, Bellet M, Dalenc F, Gil-Gil M, Ruiz-Borrego M, et al. Extended follow-up of Palbociclib with Fulvestrant or Letrozole for endocrine-sensitive, hormone receptor-positive\/HER2-negative advanced breast cancer in the PARSIFAL trial. ESMO Open. 2025;10(7):105309.","journal-title":"ESMO Open"},{"key":"2313_CR25","doi-asserted-by":"crossref","unstructured":"Valenza C, Burstein HJ. Lessons from the SONIATrial on timing of CDK4\/6 inhibitors in advanced breast cancer\u2014The Sooner, the Better? JAMA Oncol. 2026;12(4):353\u20135.","DOI":"10.1001\/jamaoncol.2025.6345"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02313-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02313-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02313-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:22:23Z","timestamp":1785885743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02313-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2313"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02313-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8764760\/v1","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the protocol review committee of the Comprehensive Support Project for Oncological Research of Breast Cancer on March 10, 2018 (approval number T2018-0026) and registered in the UMIN Clinical Trials Registry as UMIN000035863 on February 20, 2019. Ethical approval was obtained from all institutions. The study was conducted in accordance with the legal and regulatory requirements and the general principles of the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), the Guidelines of Good Clinical Practice (International Conference on Harmonization 1996), and the Declaration of Helsinki (World Medical Association 1996 and 2008). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: TI has received honoraria from AstraZeneca, Eisai, Daiichi Sankyo, Pfizer, Lilly, Chugai Pharma and MSD. His institution has received research grants from Taiho and Chugai Pharma. YU has received speaker\u2019s bureau fees from Pfizer and honoraria from Chugai Pharma. TS has received speaker\u2019s bureau fees from Pfizer, YK has received honoraria from AstraZeneca, Eisai, Daiichi Sankyo, Pfizer, Taiho, Chugai Pharma, Lilly and Novartis. AY has received honoraria from AstraZeneca, Eisai, Daiichi Sankyo, Pfizer, Lilly, Chugai Pharma, Kyowa Kirin, Takeda, Nipro Corporation and Medica, and Exact Science and research funding from Chugai Pharma and Nippon Kayaku. UT has received speaker\u2019s bureau fees from AstraZeneca, Pfizer, Lilly, Chugai Pharma, Daiichi Sankyo. HY has received honoraria from AstraZeneca, Eisai, Daiichi Sankyo, Pfizer, Lilly, Chugai Pharma and Kyowa Kirin. KN has received honoraria from AstraZeneca, Eisai, Daiichi Sankyo, Pfizer, Lilly, Chugai Pharma, Taiho, and Kyowa Kirin. His institution has received research grants from Daiichi Sankyo, Lilly and Chugai Pharma. HM has received honoraria from Taiho, Daiichi Sankyo and Takeda. All remaining authors have declared no conflicts of interest associated with this study.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"137"}}